Risperidone hexanoate | 1587586-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: Risperidone hexanoate
• 英文别名: 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one;hexanoic acid
• CAS: 1587586-95-5
• 化学式: C29H39FN4O4
• 分子量: 526.6
• InChiKey: KBFKXAXGRPWQON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.24
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Device and method for sustained release of antipsychotic medications
  申请人：DELPOR, INC.

  公开号：US10137081B2

  公开（公告）日：2018-11-27

  A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more porous partitions, where the pores of the partitions are sufficiently small to retain the insoluble powder particles within the reservoir yet large enough to allow diffusion of the active agent once the device is hydrated. A therapeutic dose of the drug is released from the device at a constant rate over a period of approximately 2-6 months.

  提供了一种药物输送装置，该装置包括一个不可腐蚀、无孔的外壳部件，外壳部件限定了一个储液器。贮液器中装有神经安定剂选定盐的干制剂。外壳部件有一个或多个多孔隔板，隔板的孔足够小，以将不溶性粉末颗粒保留在储液器内，但又足够大，以便在装置水合后允许活性剂扩散。在大约 2-6 个月的时间内，治疗剂量的药物以恒定的速度从装置中释放出来。
• DEVICE AND METHODS FOR SUSTAINED RELEASE OF ANTIPSYCHOTIC MEDICATIONS
  申请人：Delpor, Inc.

  公开号：EP2900220B1

  公开（公告）日：2018-12-12
• DEVICE AND METHOD FOR SUSTAINED RELEASE OF ANTIPSYCHOTIC MEDICATIONS
  申请人：DELPOR, INC.

  公开号：US20150250716A1

  公开（公告）日：2015-09-10

  A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more porous partitions, where the pores of the partitions are sufficiently small to retain the insoluble powder particles within the reservoir yet large enough to allow diffusion of the active agent once the device is hydrated. A therapeutic dose of the drug is released from the device at a constant rate over a period of approximately 2-6 months.